$BioNTech SE(BNTX)$ We know we'll be establishing decent Revenue in Q3...maybe the IB analysts median to high-end range is realistic. Then we have to concern ourselves with the "what about Q4 and beyond to 22/23" stuff. Some are jittery here with the unknown in that timeframe as well they should be. Lots of variables at play with Covid, variants, vax deniers, politics,, mandates, competition, etc. The future is a moving target to say the least. Looooong term we can all say we love the company and it's mRNA outlook against various diseases.
精彩评论